Comparative genomic characterization of small cell carcinoma of the bladder compared with urothelial carcinoma and small cell lung carcinoma Journal Article
| Authors: | Jaime-Casas, S.; Chawla, N. S.; Salgia, N. J.; Mercier, B.; Govindarajan, A.; Li, X.; Castro, D. V.; Ebrahimi, H.; Barragan-Carrillo, R.; Zang, P. D.; LeVee, A.; Zugman, M.; Dizman, N.; Hsu, J.; Meza, L.; Zengin, Z.; Chehrazi-Raffle, A.; Dorff, T.; Pal, S. K.; Tripathi, A. |
| Article Title: | Comparative genomic characterization of small cell carcinoma of the bladder compared with urothelial carcinoma and small cell lung carcinoma |
| Abstract: | PURPOSESmall cell bladder cancer (SCBC) is a rare histologic variant of bladder cancer with an aggressive disease course and poor outcomes. Given its uncommon nature, there is a paucity of high-quality data characterizing genomic drivers of this disease, and most patients are treated with approaches mirroring small cell lung cancer (SCLC). Leveraging the Tempus Lens deidentified clinically annotated genomic data set, we sought to evaluate the mutational landscape of SCBC relative to urothelial carcinoma (UC) and SCLC.METHODSSomatic pathogenic genomic alterations in patients with SCBC, UC, and SCLC of any stage who underwent blood-or tissue-based genomic profiling through the Tempus assay were cataloged. Baseline clinical and demographic features were compared across histologic groups. Alterations were collated and summarized using descriptive statistics. Pairwise comparisons were performed to assess differences in mutation frequency across pathologic cohorts.RESULTSIn total, 149 SCBC, 4,350 UC, and 1,697 SCLC patients were included in the study. The most common genomic alterations in SCBC were in TP53 (87%), TERT (75%), and RB1 (70%). Among SCBC patients with TP53 mutations, RB1 comutations were observed in 77% of patients. Compared with UC, SCBC patients were significantly enriched for TP53, RB1, KMT2D, and KDM6A mutations. Compared with SCLC, SCBC patients were enriched for TERT, ARID1A, and CREBBP mutations, among others (P <.05). Multiple clinically targetable mutations were observed in SCBC, including PIK3CA (19%), ERBB2/3 (13%), and ALK (10%). Limitations of this study include its retrospective nature.CONCLUSIONThis study represents one of the most extensive efforts to characterize SCBC to date, providing a novel understanding of the genomic alterations underlying the disease and revealing actionable mutations that could serve as potential targets for improved clinical outcomes. © American Society of Clinical Oncology. |
| Keywords: | adult; controlled study; middle aged; major clinical study; somatic mutation; mutation; pathogenesis; comparative study; cancer diagnosis; dna repair; statistics; cohort analysis; retrospective study; mutation rate; race difference; transitional cell carcinoma; fibroblast growth factor receptor 1; small cell lung cancer; demographics; comparative genomics; high throughput sequencing; human; male; female; article; small cell carcinoma of the bladder |
| Journal Title: | JCO Precision Oncology |
| Volume: | 9 |
| ISSN: | 2473-4284 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-04-01 |
| Start Page: | e2400947 |
| Language: | English |
| DOI: | 10.1200/po-24-00947 |
| PUBMED: | 40209138 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work